Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CDMO Stock Summary
Top 10 Correlated ETFs
CDMO
In the News
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
Avid Bioservices: Don't Miss The Bigger Picture
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.
Why Is Avid Bioservices (CDMO) Stock Down 18% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Revenue for Q2 2024
Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
Avid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q2 2024 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Tim Brons - Investors Relations Group Nick Green - President and CEO Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Max Smock - William Blair Thomas Kelliher - RBC Capital Markets Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2024 Financial Results Conference Call.
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Avid Bioservices (CDMO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.01 per share a year ago.
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
From laggards to leaders: Small caps on the rise
Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CDMO Financial details
CDMO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-04-30
Metric | History | 2019-04-30 | 2020-04-30 | 2021-04-30 | 2022-04-30 | 2023-04-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.96 | 1.06 | 1.65 | 1.72 | 2.4 | |
Net income per share | -0.08 | -0.13 | 0.19 | 1.84 | 0.01 | |
Operating cash flow per share | -0.21 | 0.1 | 0.54 | 0.14 | -0.21 | |
Free cash flow per share | -0.23 | 0.04 | 0.37 | -0.68 | -1.45 | |
Cash per share | 0.58 | 0.65 | 2.92 | 1.82 | 0.62 | |
Book value per share | 0.95 | 0.75 | 1.34 | 2.51 | 3.04 | |
Tangible book value per share | 0.95 | 0.75 | 1.32 | 2.51 | 3.04 | |
Share holders equity per share | 0.95 | 0.75 | 1.34 | 2.51 | 3.04 | |
Interest debt per share | 0 | 0.48 | 2.05 | 2.67 | 3.08 | |
Market cap | 268.15M | 342.32M | 1.25B | 934.28M | 1.11B | |
Enterprise value | 235.89M | 332.91M | 1.19B | 990.64M | 1.26B | |
P/E ratio | -63.62 | -47.18 | 111.15 | 7.32 | 1.97K | |
Price to sales ratio | 5 | 5.73 | 13 | 7.81 | 7.41 | |
POCF ratio | -23.13 | 58.75 | 39.97 | 98.71 | -85.81 | |
PFCF ratio | -20.47 | 169.89 | 58.46 | -19.9 | -12.22 | |
P/B Ratio | 5.05 | 8.17 | 16.03 | 5.35 | 5.84 | |
PTB ratio | 5.05 | 8.17 | 16.03 | 5.35 | 5.84 | |
EV to sales | 4.4 | 5.58 | 12.46 | 8.28 | 8.42 | |
Enterprise value over EBITDA | -41.96 | -32.54 | 96.52 | 64.57 | 272.99 | |
EV to operating cash flow | -20.34 | 57.13 | 38.31 | 104.66 | -97.51 | |
EV to free cash flow | -18.01 | 165.22 | 56.03 | -21.1 | -13.88 | |
Earnings yield | -0.02 | -0.02 | 0.01 | 0.14 | 0 | |
Free cash flow yield | -0.05 | 0.01 | 0.02 | -0.05 | -0.08 | |
Debt to equity | 0.07 | 0.64 | 1.52 | 1.05 | 1 | |
Debt to assets | 0.05 | 0.25 | 0.45 | 0.42 | 0.42 | |
Net debt to EBITDA | 5.74 | 0.92 | -4.18 | 3.67 | 32.74 | |
Current ratio | 2.22 | 1.34 | 2.93 | 2.38 | 1.53 | |
Interest coverage | 1.45 | -1.32K | 7.67 | 4.05 | -1 | |
Income quality | 2.75 | -0.56 | 2.78 | 0.07 | -23.01 | |
Dividend Yield | 0.02 | 0.01 | 0 | 0 | 0 | |
Payout ratio | -1.03 | -0.6 | 0.4 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.24 | 0.17 | 0.17 | 0.18 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.13 | -0.65 | -0.32 | -5.96 | 6.02 | |
Capex to revenue | -0.03 | -0.06 | -0.1 | -0.47 | -0.52 | |
Capex to depreciation | -0.55 | -1.23 | -2.86 | -12.59 | -10.77 | |
Stock based compensation to revenue | 0.03 | 0.04 | 0.04 | 0.06 | 0.07 | |
Graham number | 1.27 | 1.47 | 2.41 | 10.2 | 0.78 | |
ROIC | -0.09 | -0.08 | 0.05 | 0.27 | 0 | |
Return on tangible assets | -0.05 | -0.07 | 0.04 | 0.3 | 0 | |
Graham Net | 0.34 | -0.27 | 0.12 | -1.39 | -2.89 | |
Working capital | 28.16M | 15.28M | 136.87M | 104.26M | 38.74M | |
Tangible asset value | 53.07M | 41.9M | 76.84M | 174.88M | 189.82M | |
Net current asset value | 25.99M | -5.96M | 20.03M | -75.29M | -149.13M | |
Invested capital | 0.07 | 0.64 | 1.52 | 1.05 | 1 | |
Average receivables | 7.73M | 11.8M | 18.43M | 25.44M | 26.91M | |
Average payables | 3.13M | 5.14M | 7.59M | 9.38M | 17.05M | |
Average inventory | 11.34M | 8.72M | 11.38M | 18.97M | 34.99M | |
Days sales outstanding | 79.68 | 72.79 | 95.01 | 79.09 | 68.24 | |
Days payables outstanding | 34.25 | 38.78 | 50.76 | 41.82 | 76.21 | |
Days of inventory on hand | 51.6 | 71.23 | 65.1 | 114.68 | 136.06 | |
Receivables turnover | 4.58 | 5.01 | 3.84 | 4.61 | 5.35 | |
Payables turnover | 10.66 | 9.41 | 7.19 | 8.73 | 4.79 | |
Inventory turnover | 7.07 | 5.12 | 5.61 | 3.18 | 2.68 | |
ROE | -0.08 | -0.17 | 0.14 | 0.73 | 0 | |
Capex per share | -0.03 | -0.07 | -0.17 | -0.81 | -1.25 |
Quarterly Fundamentals Overview
Last date of statement is 2023-10-31 for Q2
Metric | History | 2022-10-31 | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.56 | 0.61 | 0.64 | 0.6 | 0.4 | |
Net income per share | -0.02 | 0.01 | 0 | -0.03 | -0.15 | |
Operating cash flow per share | -0.06 | -0.11 | 0.04 | 0 | 0.1 | |
Free cash flow per share | -0.61 | -0.29 | -0.35 | -0.23 | -0.02 | |
Cash per share | 1.24 | 0.96 | 0.62 | 0.4 | 0.5 | |
Book value per share | 2.91 | 2.97 | 3.03 | 3.03 | 2.91 | |
Tangible book value per share | 2.91 | 2.97 | 3.03 | 3.03 | 2.91 | |
Share holders equity per share | 2.91 | 2.97 | 3.03 | 3.03 | 2.91 | |
Interest debt per share | 2.93 | 2.91 | 3.04 | 2.99 | 3.11 | |
Market cap | 1.05B | 987.6M | 1.11B | 795.53M | 388.37M | |
Enterprise value | 1.16B | 1.11B | 1.26B | 959.58M | 552.24M | |
P/E ratio | -227.88 | 535.58 | -899.31 | -95.02 | -10.21 | |
Price to sales ratio | 30.32 | 25.98 | 27.93 | 21.09 | 15.29 | |
POCF ratio | -281.97 | -142.82 | 397.12 | -2.86K | 63.68 | |
PFCF ratio | -27.55 | -54.13 | -50.35 | -55.28 | -317.29 | |
P/B Ratio | 5.82 | 5.33 | 5.87 | 4.17 | 2.11 | |
PTB ratio | 5.82 | 5.33 | 5.87 | 4.17 | 2.11 | |
EV to sales | 33.31 | 29.16 | 31.72 | 25.44 | 21.75 | |
Enterprise value over EBITDA | -1.61K | 218.75 | 1.05K | -443.63 | -66.55 | |
EV to operating cash flow | -309.83 | -160.29 | 450.96 | -3.45K | 90.55 | |
EV to free cash flow | -30.27 | -60.76 | -57.17 | -66.67 | -451.17 | |
Earnings yield | 0 | 0 | 0 | 0 | -0.02 | |
Free cash flow yield | -0.04 | -0.02 | -0.02 | -0.02 | 0 | |
Debt to equity | 1 | 0.97 | 1 | 0.99 | 1.06 | |
Debt to assets | 0.41 | 0.4 | 0.42 | 0.43 | 0.43 | |
Net debt to EBITDA | -144.58 | 23.85 | 124.85 | -75.84 | -19.75 | |
Current ratio | 1.77 | 1.52 | 1.53 | 1.53 | 1.35 | |
Interest coverage | -3.82 | 4.38 | -0.89 | 2.79 | -13.94 | |
Income quality | 3.23 | -15 | -9.06 | 0.13 | -0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.17 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 9.23 | 1.64 | -8.89 | 50.77 | -1.2 | |
Capex to revenue | -0.99 | -0.3 | -0.63 | -0.37 | -0.29 | |
Capex to depreciation | -18.97 | -5.91 | -13.2 | -5.33 | -2.63 | |
Stock based compensation to revenue | 0.08 | 0.07 | 0.09 | 0.06 | 0.1 | |
Graham number | 1.1 | 0.7 | 0.58 | 1.51 | 3.14 | |
ROIC | 0 | 0 | 0 | 0 | -0.02 | |
Return on tangible assets | 0 | 0 | 0 | 0 | -0.02 | |
Graham Net | -2.31 | -2.62 | -2.88 | -3.09 | -3.2 | |
Working capital | 63.56M | 45.02M | 38.74M | 34.26M | 27.27M | |
Tangible asset value | 181.55M | 185.75M | 189.82M | 190.95M | 183.68M | |
Net current asset value | -114.71M | -132.69M | -149.13M | -153.42M | -166.76M | |
Invested capital | 1 | 0.97 | 1 | 0.99 | 1.06 | |
Average receivables | 30.07M | 26.16M | 26.56M | 22.06M | 20.22M | |
Average payables | 26.89M | 29.86M | 30.49M | 23.7M | 22.8M | |
Average inventory | 34.71M | 42.08M | 44.51M | 42.39M | 39.72M | |
Days sales outstanding | 70.19 | 59.69 | 63.11 | 38.67 | 85.86 | |
Days payables outstanding | 68.59 | 116.17 | 70.47 | 61.06 | 68.22 | |
Days of inventory on hand | 114.85 | 143.98 | 125.82 | 109.38 | 115.52 | |
Receivables turnover | 1.28 | 1.51 | 1.43 | 2.33 | 1.05 | |
Payables turnover | 1.31 | 0.77 | 1.28 | 1.47 | 1.32 | |
Inventory turnover | 0.78 | 0.63 | 0.72 | 0.82 | 0.78 | |
ROE | -0.01 | 0 | 0 | -0.01 | -0.05 | |
Capex per share | -0.55 | -0.18 | -0.4 | -0.22 | -0.12 |
CDMO Frequently Asked Questions
What is Avid Bioservices, Inc. stock symbol ?
Avid Bioservices, Inc. is a US stock , located in Tustin of Ca and trading under the symbol CDMO
What is Avid Bioservices, Inc. stock quote today ?
Avid Bioservices, Inc. stock price is $6.98 today.
Is Avid Bioservices, Inc. stock public?
Yes, Avid Bioservices, Inc. is a publicly traded company.